Forkhead box protein P1 as a downstream target of transforming growth factor-β induces collagen synthesis and correlates with a more stable plaque phenotype

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 33-43

  Bot, Pieter T ^a,b   Grundmann, Sebastian ^c   Goumans, Marie José ^d   de Kleijn, Dominique ^e   Moll, Frans ^b   de Boer, Onno ^a   van der Wal, Allard C ^a   van Soest, Alex ^b   de Vries, Jean Paul ^f   van Royen, Niels ^a   Piek, Jan J ^a   Pasterkamp, Gerard ^b   Hoefer, Imo E ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Atherosclerosis; Macrophages; Plaque stability; Smooth muscle cells; TGF

Indexed keywords

COLLAGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ENDARTERECTOMY; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY DISEASE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; WESTERN BLOTTING;

AGED; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; FEMALE; FIBROSIS; FORKHEAD TRANSCRIPTION FACTORS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; REPRESSOR PROTEINS; THROMBOSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 80052260513     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.017     Document Type: Article

References (30)

1. Ross R. Mechanisms of disease - Atherosclerosis - An inflammatory disease. N Engl J Med 1999, 340(2):115-126.
2. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20(5):1262-1275.
3. Webb N.R., Moore K.J. Macrophage-derived foam cells in atherosclerosis: lessons from murine models and implications for therapy. Curr Drug Targets 2007, 8(12):1249-1263.
4. Shi C., Zhang X., Chen Z., et al. Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. J Clin Invest 2004, 114(3):408-418.
5. Shu W., Yang H., Zhang L., Lu M.M., Morrisey E.E. Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J Biol Chem 2001, 276(29):27488-27497.
6. Banham A.H., Beasley N., Campo E., et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 2001, 61(24):8820-8829.
7. Zhang Y., Li S., Yuan L., et al. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev 2010, 24(16):1746-1757.
8. Feng X., Ippolito G.C., Tian L., et al. Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development. Blood 2010, 115(3):510-518.
9. Wang B., Lin D., Li C., Tucker P. Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem 2003, 278(27):24259-24268.
10. Bettelli E., Dastrange M., Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A 2005, 102(14):5138-5143.
11. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86(2):515-581.
12. Verhoeven B.A., Velema E., Schoneveld A.H., et al. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol 2004, 19(12):1127-1133.
13. Bot P.T., Hoefer I.E., Sluijter J.P., et al. Increased expression of the transforming growth factor-beta signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 2009, 40(2):439-447.
14. Inman G.J., Nicolas F.J., Callahan J.F., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62(1):65-74.
15. Wang B., Weidenfeld J., Lu M.M., et al. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 2004, 131(18):4477-4487.
16. Verhoeven B., Hellings W.E., Moll F.L., et al. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg 2005, 42(6):1075-1081.
17. Kolodgie F.D., Gold H.K., Burke A.P., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003, 349(24):2316-2325.
18. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005, 25(10):2054-2061.
19. Conley B.A., Smith J.D., Guerrero-Esteo M., Bernabeu C., Vary C.P. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000, 153(2):323-335.
20. Lastres P., Letamendia A., Zhang H., et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 1996, 133(5):1109-1121.
21. Barbara N.P., Wrana J.L., Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999, 274(2):584-594.
22. Chen S.J., Ning H., Ishida W., et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006, 281(30):21183-21197.
23. Santiago F.S., Lowe H.C., Kavurma M.M., et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999, 5(12):1438.
24. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten D.P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002, 21(7):1743-1753.
25. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 2006, 26(8):1712-1720.
26. Santos M.E., Athanasiadis A., Leitao A.B., Dupasquier L., Sucena E. Alternative splicing and gene duplication in the evolution of the FoxP gene subfamily. Mol Biol Evol 2011, 28(1):237-247.
27. Hannenhalli S., Putt M.E., Gilmore J.M., et al. Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 2006, 114(12):1269-1276.
28. Shu W., Lu M.M., Zhang Y., Tucker P.W., Zhou D., Morrisey E.E. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development 2007, 134(10):1991-2000.
29. Grant C., Oh U., Fugo K., et al. Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog 2006, 2(4):e33.
30. Li B., Samanta A., Song X., et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int Immunol 2007, 19(7):825-835.